
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
Key Takeaways
- Pertuzumab-qcay is indicated with trastuzumab and docetaxel for first-line HER2-positive metastatic breast cancer without prior anti-HER2 therapy or chemotherapy in the metastatic setting.
- Neoadjuvant use covers HER2-positive locally advanced, inflammatory, or early-stage disease within a complete regimen, and adjuvant use targets high-risk early breast cancer.
Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.
The FDA has approved pertuzumab-qcay (Pebrilzo), a biosimilar referencing pertuzumab (Perjeta), for combination use with trastuzumab (Herceptin) in patients with HER2-positive breast cancer across 3 settings: metastatic disease, neoadjuvant therapy, and adjuvant therapy for early disease at high risk of recurrence.¹
This regulatory decision was based on structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, which showed no clinically meaningful differences from the reference product in terms of quality, safety, efficacy, or immunogenicity.
The approved indications for pertuzumab-qcay are:
- In combination with trastuzumab (Herceptin) and docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have received no prior anti-HER2 therapy or chemotherapy for the management of metastatic disease
- The neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early disease
- The adjuvant treatment of adult patients with HER2-positive, high-risk, early breast cancer
“The United States FDA approval of [pertuzumab-qcay], our biosimilar [referencing] pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars,” Shreehas Tambe, chief executive officer and managing director of Biocon Limited, stated in a news release. “For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive United States FDA approval, [pertuzumab-qcay] strengthens our anticancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
What are the FDA-approved indications for reference pertuzumab?
Pertuzumab is FDA approved for use in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer and no prior anti-HER2 therapy or chemotherapy in the metastatic setting.² In early disease, it is approved in combination with trastuzumab and chemotherapy as neoadjuvant therapy for adult patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer (greater than 2 cm or node-positive) within a complete early breast cancer regimen, and as adjuvant therapy for adult patients with HER2-positive early disease at high risk of recurrence.
What is the regulatory status of pertuzumab-qcay for HER2-positive breast cancer in Europe?
On September 22, 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending marketing authorization of pertuzumab-qcay, supplied as a 420-mg concentrate for solution for infusion, for the same 3 breast cancer indications.³ Pertuzumab-qcay is the first monoclonal antibody biosimilar to receive a positive Committee for Medicinal Products for Human Use (CHMP) opinion under the European Medicines Agency’s tailored clinical development approach, which is described in a reflection paper the CHMP adopted on March 16, 2026.
Under that approach, a biosimilar may be approved without a dedicated comparative efficacy study if analytical comparability, in vitro pharmacology, and a comparative pharmacokinetic trial are sufficient to infer similar clinical efficacy and safety. The European Commission has not issued a final decision, and the product is not yet authorized in the European Union.
What is the safety profile of pertuzumab-qcay?
The label for pertuzumab-qcay includes a boxed warning for left ventricular dysfunction and embryo-fetal toxicity, with discontinuation advised after a confirmed, clinically significant decline in left ventricular function.¹ Pertuzumab-qcay is contraindicated in patients with known hypersensitivity to pertuzumab or its excipients, and warnings cover infusion-related reactions and hypersensitivity or anaphylaxis. The most common adverse effects, seen in more than 30% of patients, differ by indication and include diarrhea, alopecia, neutropenia, nausea, and fatigue.
References
- Biocon gets U.S. FDA approval for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, expanding its oncology portfolio. News release. Biocon Limited. November 16, 2026. Accessed November 16, 2026. https://www.businesswire.com/news/home/20261116435734/en/Biocon-Gets-U.S.-FDA-Approval-for-Pebrilzo-pertuzumab-qcay-Injection-a-Biosimilar-to-Perjeta-Expanding-Its-Oncology-Portfolio
- Perjeta. Prescribing information. Genentech; 2026. Accessed November 16, 2026. https://www.gene.com/download/pdf/perjeta_prescribing.pdf
- Biocon’s pertuzumab biosimilar earns CHMP nod under EMA’s new tailored pathway. BioPharm International. September 22, 2026. Accessed November 16, 2026. https://www.biopharminternational.com/view/biocon-s-pertuzumab-biosimilar-earns-chmp-nod-under-ema-s-new-tailored-pathway
Related to this article








